نتائج البحث - Marcel Reiser

  • يعرض 1 - 17 نتائج من 17
تنقيح النتائج
  1. 1
    Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma

    Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma حسب Julia Bohlius, Christine Herbst, Marcel Reiser, Guido Schwarzer, Andreas Engert

    منشور في 2008
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin’s lymphoma: results from the NHL-B trial of the GermanHigh-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL)

    Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin’s lymphoma: results from the NHL-B trial of the GermanHig... حسب A. Wunderlich, Marita Kloess, Marcel Reiser, Christian Rudolph, Lorenz Truemper, Stefan Bittner, Harald Schmalenberg, Rudolf Schmits, Michael Pfreundschuh, Markus Loeffler

    منشور في 2003
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Time-intensified dexamethasone/cisplatin/cytarabine:an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin’s disease

    Time-intensified dexamethasone/cisplatin/cytarabine:an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin’s disease حسب Andreas Josting, Christian Rudolph, Marcel Reiser, MY Mapara, M. Sieber, Hartmut Kirchner, Bernd Dörken, Dieter K. Hossfeld, Volker Diehl, Andreas Engert

    منشور في 2002
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma

    Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma حسب H. Schulz, Julia Bohlius, Nicole Skoetz, Sven Trelle, Thilo Kober, Marcel Reiser, Martin Dreyling, Michael Herold, Guido Schwarzer, Michael Hallek, Andreas Engert

    منشور في 2007
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)

    Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG) حسب H. Schulz, U. Rehwald, Franck Morschhauser, Thomas Elter, Christoph Driessen, Thomas Rüdiger, Peter Borchmann, Roland Schnell, Volker Diehl, Andreas Engert, Marcel Reiser

    منشور في 2007
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group

    Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study... حسب U. Rehwald, H. Schulz, Marcel Reiser, Markus Sieber, Jan Oliver Staak, Franck Morschhauser, Christoph Driessen, Thomas Rüdiger, Konrad Müller-Hermelink, Volker Diehl, Andreas Engert

    منشور في 2002
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients

    Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients حسب Gerd Fätkenheuer, Albert Theisen, Jürgen K. Rockstroh, Tanja Grabow, Christian Wicke, Katja Becker, Ulrike Wieland, Herbert Pfister, Marcel Reiser, P Hegener, Caspar Franzen, Achim Schwenk, Bernd Salzberger

    منشور في 1997
    احصل على النص الكامل
    Carta
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo

    A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multip... حسب Elke Pogge von Strandmann, Hinrich P. Hansen, Katrin S. Reiners, Roland Schnell, Peter Borchmann, Sabine Merkert, Venkateswara R. Simhadri, Andreas Draube, Marcel Reiser, Ingvill Purr, Michael Hallek, Andreas Engert

    منشور في 2005
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL

    The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL حسب Carsten Müller, Niels Murawski, Martin H. J. Wiesen, Gerhard Held, Viola Poeschel, Samira Zeynalova, Michael Wenger, Christina Nickenig, Norma Peter, Eva Lengfelder, Bernd Metzner, Tanja Rixecker, Carsten Zwick, Michael Pfreundschuh, Marcel Reiser

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma

    Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma حسب A. Herrmann, Eva Hoster, Thomas Zwingers, Günter Brittinger, M. Engelhard, P. Meusers, Marcel Reiser, Roswitha Forstpointner, Bernd Metzner, Norma Peter, Bernhard Wörmann, Lorenz Trümper, Michael Pfreundschuh, Hermann Einsele, Wolfgang Hiddemann, Michael Unterhalt, Martin Dreyling

    منشور في 2008
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas

    Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lympho... حسب Agnieszka Korfel, Thomas Elter, E. Thiel, Matthias Hänel, Robert Möhle, Roland Schroers, Marcel Reiser, M. Dreyling, Jan Eucker, Christian W. Scholz, Bernd Metzner, Alexander Röth, J. Birkmann, Uwe Schlegel, P. Martus, Gerald Illerhaus, L. Fischer

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    Fludarabine in Combination With Alemtuzumab Is Effective and Feasible in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia: Results of a Phase II Trial

    Fludarabine in Combination With Alemtuzumab Is Effective and Feasible in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia: Results of a Phase II Trial حسب Thomas Elter, Peter Borchmann, H. Schulz, Marcel Reiser, Sven Trelle, Roland Schnell, Markus Jensen, Peter Staib, Timo Schinköthe, H. Stützer, Jürgen Rech, Martin Gramatzki, Walter E. Aulitzky, Ibrahim Hasan, Andreas Josting, Michael Hallek, Andreas Engert

    منشور في 2005
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia

    The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia حسب Petra Langerbeins, Can Zhang, Sandra Robrecht, Paula Cramer, Moritz Fürstenau, Othman Al‐Sawaf, Julia von Tresckow, Anna‐Maria Fink, Karl‐Anton Kreuzer, Ursula Vehling‐Kaiser, Eugen Tausch, Lothar Müller, Michael J. Eckart, Rudolf Schlag, W. Freier, Tobias Gaska, Christina Balser, Marcel Reiser, Martina Stauch, Clemens‐Martin Wendtner, Kirsten Fischer, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek

    منشور في 2021
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)

    Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-... حسب Frank Griesinger, Wilfried Eberhardt, Arnd Nusch, Marcel Reiser, Mark‐Oliver Zahn, Christoph Maintz, Christiane Bernhardt, Christoph Losem, Albrecht Stenzinger, Lukas C. Heukamp, Reinhard Büttner, Norbert Marschner, Martina Jänicke, A. Fleitz, Lisa Spring, Jörg Sahlmann, Aysun Karatas, A. Hipper, Wilko Weichert, Monika Heilmann, Parvis Sadjadian, Wolfgang Gleiber, Christian Grah, Cornelius F. Waller, Martin Reck, Achim Rittmeyer, Petros Christopoulos, Martin Sebastian, Michael Thomas

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer

    Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer حسب Hans‐Ulrich Schildhaus, Lukas C. Heukamp, Sabine Merkelbach‐Bruse, Katarina Riesner, Katja Schmitz, Elke Binot, Ellen Paggen, Kerstin Albus, Wolfgang Schulte, Yon‐Dschun Ko, Andreas Schlesinger, Sascha Ansén, Walburga Engel-Riedel, Michael Brockmann, Monika Serke, Ulrich Gerigk, Sebastian Huss, Friederike Göke, Sven Perner, Khosro Hekmat, Konrad Frank, Marcel Reiser, Roland Schnell, Marc Bos, Christian Mattonet, Martin L. Sos, Erich Stoelben, Jürgen Wolf, Thomas Zander, Reinhard Buettner

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    A Genomics-Based Classification of Human Lung Tumors

    A Genomics-Based Classification of Human Lung Tumors حسب Danila Seidel, Thomas Zander, Lukas C. Heukamp, Martin Peifer, Marc Bos, Lynnette Fernández-Cuesta, Frauke Leenders, Xin Lü, Sascha Ansén, Masyar Gardizi, Chau Nguyen, Johannes Berg, Prudence A. Russell, Zoe Wainer, Hans‐Ulrich Schildhaus, Toni-Maree Rogers, Benjamin Solomon, William Pao, Scott L. Carter, Gad Getz, D. Neil Hayes, Matthew D. Wilkerson, Erik Thunnissen, William D. Travis, Sven Perner, Gavin Wright, Élisabeth Brambilla, Reinhard Buettner, Juergen Wolf, Roman K. Thomas, Franziska Gabler, Ines Wilkening, Christian Mueller, Ilona Dahmen, Roopika Menon, Katharina Koenig, Kerstin Albus, Sabine Merkelbach‐Bruse, Jana Fassunke, Katja Schmitz, Helen Kuenstlinger, Michaela Angelika Kleine, Elke Binot, Silvia Querings, Janine Altmueller, Ingelore Boessmann, Peter Nuemberg, Peter M. Schneider, Magdalena Bogus, Alex Soltermann, Holger Moch, Odd Terje Brustugun, Steinar Solberg, Marius Lund‐Iversen, Åslaug Helland, Thomas Muley, Hans Hoffmann, Philipp A. Schnabel, Yuan Chen, Harry J.M. Groen, Wim Timens, Hannie Sietsma, Joachim H. Clement, Walter Weder, Joerg Saenger, Erich Stoelben, Corinna Ludwig, Walburga Engel-Riedel, Egbert F. Smit, Danille A. M. Heideman, Peter J.F. Snijders, Lucia Nogová, Martin L. Sos, Christian Mattonet, Karin Toepelt, Matthias Scheffler, Eray Goekkurt, Rainer Kappes, Stefan Krueger, Kato Kambartel, Dirk Behringer, Wolfgang Schulte, Wolfgang Galetke, Winfried Randerath, Matthias Heldwein, Andreas Schlesinger, Monika Serke, Khosro Hekmat, Konrad Frank, Roland Schnell, Marcel Reiser, Ali-Nuri Huenerlituerkoglu, Stephan Schmitz, Lisa Meffert, Yon‐Dschun Ko, Markus Litt-Lampe, Ulrich Gerigk, Rainer Fricke, Benjamin Besse, Christian Brambilla

    منشور في 2013
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    Adjuvant <i>nab</i>-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial

    Adjuvant <i>nab</i>-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial حسب Margaret A. Tempero, Uwe Pelzer, Eileen M. O’Reilly, Jordan M. Winter, Do‐Youn Oh, Chung–Pin Li, Giampaolo Tortora, Heung-Moon Chang, Charles D. Lopez, Tanios Bekaii‐Saab, Andrew H. Ko, Armando Santoro, Joon Oh Park, Marcus Smith Noel, Giovanni Luca Frassineti, Yan‐Shen Shan, Andrew Dean, Hanno Riess, Eric Van Cutsem, Jordan Berlin, Philip Philip, Malcolm J. Moore, David Goldstein, Josep Tabernero, Mingyu Li, Stefano Ferrara, Yvan Le Bruchec, George Zhang, Brian Lu, Andrew V. Biankin, Michele Reni, Richard A. Epstein, Paul L. Vasey, Jeremy Shapiro, Matthew Burge, Yu Jo Chua, Marion Harris, Nick Pavlakis, Niall C. Tebbutt, Gerald W. Prager, Christian Dittrich, Alois Lang, Kathrin Philipp‐Abbrederis, Richard Greil, Herbert Stöger, Michael Girschikofsky, Thomas Kuehr, Jean–Luc Van Laethem, Stéphanie Laurent, Neesha C. Dhani, Yoo Joung Ko, Scot Dowden, Petr Kavan, Mustapha Édouard Tehfe, Eugen Kubala, Milan Kohoutek, Per Pfeiffer, Mette Yilmaz, Vibeke K. Parner, Tapio Salminen, Leena‐Maija Soveri, Eija Korkeila, Pia Österlund, Julien Taı̈eb, David Tougeron, Pascal Artru, François‐Xavier Caroli‐Bosc, Rosine Guimbaud, Anthony Turpin, Thomas Walter, Jean‐Baptiste Bachet, Volker Kunzmann, Florian Kreth, Andreas De Block, Marino Venerito, Helmut Oettle, Meinolf Karthaus, Jörg Trojan, Gunnar Folprecht, Markus M. Lerch, Frank Kullmann, Marcel Reiser, Volker Heinemann, Marcus‐Alexander Wörns, H. Schulz, Benjamin Garlipp, Thomas Yau, Lam Stephen Chan, Balázs Juhász, László Landherr, Tamás Pintér, G. Bodoky, Zsuzsanna Kahán, Ray McDermott, Derek G. Power, Luca Gianni, Salvatore Siena, Michèle Milella, Alfredo Falcone, Rossana Berardi

    منشور في 2022
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: